Objective To evaluate the feasibility and safety of a step-down de-escalation strategy for antihypertensive medications and its effect on cardiac function in patients with heart failure with reduced ejection fraction (HFrEF) who achieved improved left ventricular ejection fraction (LVEF) after sacubitril/valsartan therapy.Methods A total of 120 HFrEF patients with improved LVEF (≥45%) after sacubitril/valsartan therapy, admitted to the Department of Cardiovascular Medicine of Xinyang Central Hospital from January 2024 to March 2025, were enrolled. Using a random number table, patients were assigned to a step-down group (n=60) and a conventional treatment group (n=60). Throughout the 24-week study period, both groups maintained sacubitril/valsartan at the target dose or maximum tolerated dose and received standard foundational therapy. Meanwhile, the step-down group underwent gradual reduction in the number and dosage of antihypertensive agents according to a prespecified step-down protocol, whereas the conventional treatment group continued their original regimen without active de-escalation. The primary outcomes (heart failure rehospitalization, all-cause mortality, major adverse cardiovascular events [MACE], and adverse reactions) and secondary outcomes (blood pressure, LVEF, left ventricular end-diastolic diameter [LVEDD], N-terminal pro-B-type natriuretic peptide [NT-proBNP] levels, and the number and dosage of antihypertensive agents) were compared between the two groups. Results The incidence of hypotension was 5.00% (3/60) in the step-down group, lower than 16.67% (10/60) in the conventional treatment group (P<0.05). No significant between-group differences were observed in heart failure rehospitalization, all-cause mortality, MACE, hyperkalemia, or worsening renal function (all P>0.05). No significant between-group differences were found in systolic blood pressure, diastolic blood pressure, LVEF, LVEDD, or NT-proBNP levels at baseline or at 24 weeks (all P>0.05). Compared with baseline, LVEF increased in the step-down group at 24 weeks, and LVEDD and NT-proBNP levels decreased in both groups (all P<0.05). At 24 weeks, the step-down group used fewer antihypertensive agents and had a lower defined daily dose than the conventional treatment group (both P<0.05). Conclusion Under continuous sacubitril/valsartan maintenance and close monitoring, a step-down de-escalation strategy for antihypertensive medications reduces the number and dosage of antihypertensive agents and lowers the risk of hypotension in HFrEF patients with improved LVEF after sacubitril/valsartan therapy, without increasing MACE risk, deteriorating cardiac function, or compromising blood pressure control.